Yifan Zhang

5PUBLICATIONS
6CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 30, 2026
Histone methyltransferase KMT2D promotes castration-resistant prostate cancer progression by reactivating AR through FOXA1.

|May 29, 2026
Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonism.

|Mar 26, 2026
SMARCA4 promotes lineage plasticity and enzalutamide resistance in prostate cancer by regulating PROX1 via H3K27 acetylation.

Chenwei Wu, Mayao Luo, Chaojian Wu

|Feb 27, 2026
UHRF1 regulates AR ubiquitination to promote the loss of AR signaling and enzalutamide resistance in progression of prostate cancer.

Yifan Zhang, Zhaojun Yu, Yadong Li

|Aug 07, 2023
IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.

Yifan Zhang, Yuanpeng Liao, Mayao Luo

Pageof 1

Frequent Collaborators

4 joint publications

Qiang Wei

2 joint publications

Shidong Lv

2 joint publications

Hailiang Hu

1 joint publications

Chris Soon Heng Tan